A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC).
Howard A. Burris
No relevant relationships to disclose
Michael S. Gordon
Honoraria - Genentech
Research Funding - Genentech
David E. Gerber
Honoraria - Genentech
Research Funding - Genentech
David R. Spigel
No relevant relationships to disclose
David S. Mendelson
No relevant relationships to disclose
Joan H. Schiller
No relevant relationships to disclose
Yulei Wang
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Younjeong Choi
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Robert S. Kahn
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Katie Wood
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Daniel J. Maslyar
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Jeffrey R. Infante
No relevant relationships to disclose